Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract

By Winquist E.   Ernst D.S.   Jonker D.   Moore M.J.   Segal R.   Lockwood G.   Rodgers A.  

European Journal of Cancer, Vol. 39, Iss. 13, 2003-09 ,pp. : 1866-1871

Elsevier

Access to resources Recommend Favorite

First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study

By Papakostas P.   Kouroussis C.   Androulakis N.   Samelis G.   Aravantinos G.   Kalbakis K.   Sarra E.   Souglakos J.   Kakolyris S.   Georgoulias V.  

European Journal of Cancer, Vol. 37, Iss. 15, 2001-10 ,pp. : 1833-1838

Elsevier

Access to resources Recommend Favorite

Radiation treatment outcomes for unresectable hepatocellular carcinoma

By Skinner Heath D.   Sharp Hadley J.   Kaseb Ahmed O.   Javle Milind M.   Vauthey Jean Nicolas   Abdalla Eddie K.   Delclos Marc E.   Das Prajnan   Crane Christopher H.   Krishnan Sunil  

Acta Oncologica, Vol. 50, Iss. 8, 2011-11 ,pp. : 1191-1198

Informa Healthcare

Access to resources Recommend Favorite

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma

By Koh Y.   Lim H. Y.   Ahn J. H.   Lee J.-L.   Rha S. Y.   Kim Y. J.   Kim T. M.   Lee S.-H.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1026-1031

Oxford University Press

Access to resources Recommend Favorite

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

By            

Oncology Reports, Vol. 28, Iss. 3, 2012-01 ,pp. : 763-767

Spandidos Publications

Access to resources Recommend Favorite